Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Equity Average (2017 - 2025)

Historic Equity Average for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $656.7 million.

  • Protagonist Therapeutics' Equity Average rose 2238.23% to $656.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $656.7 million, marking a year-over-year increase of 2238.23%. This contributed to the annual value of $506.0 million for FY2024, which is 8323.37% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Equity Average stood at $656.7 million for Q3 2025, which was up 2238.23% from $678.5 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Equity Average ranged from a high of $682.2 million in Q1 2025 and a low of $215.9 million during Q1 2023
  • Its 5-year average for Equity Average is $397.5 million, with a median of $314.8 million in 2021.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 27785.88% in 2021, then crashed by 2825.26% in 2023.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Equity Average stood at $314.8 million in 2021, then decreased by 27.07% to $229.6 million in 2022, then surged by 39.11% to $319.4 million in 2023, then surged by 88.97% to $603.6 million in 2024, then rose by 8.8% to $656.7 million in 2025.
  • Its Equity Average was $656.7 million in Q3 2025, compared to $678.5 million in Q2 2025 and $682.2 million in Q1 2025.